Thrombocytosis in Ovarian Cancer May be Countered with Direct Antiplatelet Strategies

Share this content:

(ChemotherapyAdvisor) – Thrombocytosis is significantly associated with advanced disease and shorted survival in patients with epithelial ovarian cancer, a study published in February 16 issue of The New England Journal of Medicine reported. These data suggest that “paraneoplastic thrombocytosis may be not simply an epiphenomenon of cancer progression but a contributor to the process,” the investigators stated.

Clinical data on 619 patients were analyzed to test whether an association existed between platelet counts and disease outcomes. Underlying mechanisms were explored using human samples and mouse models of epithelial ovarian cancer and effects of platelets on tumor growth and angiogenesis determined.

Compared to those without thrombocytosis, patients with thrombocytosis had significantly elevated plasma levels of thrombopoietin and interleukin-6. Thrombocytosis was abrogated in tumor-bearing mice by silencing thrombopoietin and interleukin-6 and, in tumor-bearing mice and in patients with epithelial ovarian cancer, anti–interleukin-6 antibody treatment significantly reduced platelet counts.

“These findings support the existence of a paracrine circuit wherein increased production of thrombopoietic cytokines in tumor and host tissue leads to paraneoplastic thrombocytosis, which fuels tumor growth,” they noted. “In addition, neutralizing interleukin-6 significantly enhanced the therapeutic efficacy of paclitaxel in mouse models of epithelial ovarian cancer.”

Countering paraneoplastic thrombocytosis with the use of direct antiplatelet strategies may provide a valuable therapeutic approach, the investigators concluded. One in three women with ovarian cancer has thrombocytosis and is therefore at risk for thromboembolic complications.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs